

Figura 1




Figura 2

Fig 2A:
EGF-HSA-C1-C2
(FP330)




Fig 2B:
EGF-HSA-C1-C2 de EDIL3
(FP050)



Fig 2C:
EGF-Fc(KIH)-C1-C2
no reducido y reducido
(FP071 + Fc-IgG1 (oja))




Fig 2D:
EGF-HSA-C1
(FP260)





Fig 2E: Análisis SDS-PAGE de MFG-E8 truncado, fusiones HSA y proteínas quiméricas MFG-E8/EDIL-3



Línea 1, 12:	Marcador de peso molecular (Biorad, Precision plus protein)		
Línea 2:	His6_EGF[MFG-E8]_C1[MFG-E8]		23,87kDa
Línea 3:	EGF[MFG-E8]_C1[MFG-E8]_His6	SEQ ID 115	23,87kDa
Línea 4:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 117	90,38kDa
Línea 5:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 74	89,27kDa
Línea 6:	EGF[MFG-E8]_HSA_C1[MFG-E8]	SEQ ID 73	88,72kDa
Línea 7:	EGF[EDIL3]_HSA_C1[EDIL3]	SEQ ID 71	98,22kDa
Línea 8:	EGF[EDIL3]_HSA_C2[EDIL3]	SEQ ID 135	98,20kDa
Línea 9:	EGF[MFG-E8]_HSA_C2[MFG-E8]	SEQ ID 137	88,45kDa
Línea 10:	EGF[EDIL3]_HSA_C1_C2[MFG-E8]	SEQ ID 80	115,67kDa
Línea 11:	EGF[MFG-E8]_HSA_C1_C2[EDIL3]	SEQ ID 82	107,32kDa

Figura 3

Fig 3A
WT MFG-E8 (EGF-C1-C2)





Fig 3B
FP278 (Etiqueta EGF-HSA-C1-C2-His)



Diluciones hechas en ● Placas sin unión ◻ Placas de polipropileno

Figura 4

Fig 4A




Fig 4B




Figura 5

Fig 5A




Fig 5B




Fig 5C




Fig 5D




Figura 6




Figura 7

Fig 7A




Fig 7B




Figura 8

Fig 8A




Fig 8B




Figura 9




Figura 10




Figura 11

Fig 11A




Fig 11B




Fig 11C




Fig 11D




Fig 11E




Fig 11F

Proteína de fusión que comprende dominios de GAS6/PROS1




Fig 11G

Proteína de fusión que comprende dominios del Factor VIII (Turoctocog alfa modificado)




Fig 11H

Representación esquemática de un ejemplo de proteína de fusión recombinante que comprende dominios de trombomodulina (CD141)




Fig 11I

Representación esquemática de un ejemplo de proteína de fusión recombinante que comprende dominios del receptor C1q del componente del complemento (CD93)




Figura 12




Figura 13

Fig 13A




Fig 13B




Fig 13C




Fig 13D




Fig 13E




Figura 14

Fig 14A




Fig 14B




Fig 14C




Figura 15

Fig 15A




Fig 15B




Fig 15C




Figura 16




Figura 17

Fig 17A




Fig 17B




Figura 18




Fig 19




Fig 20

Rigidez del hígado por Elastografía de Ondas de Corte




Fig 21A

**Niveles de ALT en el día 3 en relación con el día de interrupción de CCL4
(análisis emparejado)**




Fig 21B




Figure 21C




Figura 22




Figura 23 Radio hidrodinámico de EGF-C1 y EGF-HSA-C1 medido a 3 mg/mL en PBS, pH 7,4 bajo estrés térmico

